Likacin

Amikacin, the active ingredient in Likacin, is an aminoglycoside presented as a sterile powder for injection for intramuscular and intravenous use. It treats serious infections caused by susceptible Gram‑negative bacteria in hospitalized patients, including severe urinary tract infections, hospital‑acquired pneumonia, and septicemia.

GNH USA supplies Likacin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and regulatory requirements. The company ensures reliable cold‑chain logistics and comprehensive documentation for export throughout the export process.

Amikacin is used to treat infections caused by susceptible Gram‑negative bacteria.

- Severe urinary tract infections: eradicates susceptible Gram‑negative pathogens causing complicated UTIs. - Hospital‑acquired pneumonia: provides bactericidal activity against resistant Gram‑negative organisms in the lungs. - Complicated intra‑abdominal infections: targets Gram‑negative bacteria involved in peritonitis and abscesses. - Septicemia (bloodstream infection): delivers rapid bacterial kill in systemic Gram‑negative infections. - Febrile neutropenia: used as part of combination therapy for Gram‑negative sepsis in neutropenic patients. - Bone and joint infections: administered for osteomyelitis caused by susceptible Gram‑negative organisms.

Amikacin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nephrotoxicity: elevated serum creatinine and reduced glomerular filtration. - Ototoxicity: high‑frequency hearing loss or tinnitus. - Neuromuscular blockade: muscle weakness or respiratory depression. - Injection site reactions: pain, erythema, or swelling at the administration site.

Serious or Rare Side Effects: - Acute renal failure: sudden loss of kidney function requiring dialysis. - Permanent hearing loss: irreversible auditory damage. - Anaphylaxis: severe allergic reaction with hypotension and airway compromise. - Balance disturbances: vertigo or loss of equilibrium.

Before initiating amikacin therapy, clinicians should consider several precautionary measures. - Renal function monitoring: assess serum creatinine and urine output before and during treatment. - Audiometric testing: obtain baseline hearing assessment and repeat periodically. - Pregnancy risk: use only when benefits outweigh potential fetal harm. - Concomitant nephrotoxic drugs: avoid or adjust dose when given with other renal toxins. - Dosage adjustment in the elderly: consider reduced clearance and monitor levels. - Store at ambient temperature: keep in original container, protect from moisture and light.

Amikacin can interact with other medicines, influencing its safety and effectiveness.

Major Interactions (Avoid): - Co‑administration with other aminoglycosides: markedly increased risk of nephro‑ and ototoxicity. - Loop diuretics (e.g., furosemide): synergistic renal toxicity. - Neuromuscular blocking agents (e.g., vecuronium): enhanced muscle paralysis.